Sirius is an innovative biotech company developing novel RNAi therapies for global markets. We are dedicated to providing solutions for physicians and patients to manage cardiovascular diseases. Our aim is to be a leading developer of RNAi therapeutics for the management of chronic diseases.

Sirius was founded in 2021 with a world-class leadership team and investors. After founding in 2021, Sirius established an innovation, research and development center in the United States and a translational center in China to address unmet patient needs in chronic disease.  Leveraging RNAi technology, we offer a portfolio of solutions for patients to change the future of cardiovascular disease.

Key Milestones

2023

  • September

    Completed Series B financing

  • August

    Submitted the first IND to China NMPA

2022

  • November

    Established company’s new office in Shanghai,China

  • July

    Completed Series A financing

  • March

    Sirius China was officially established

2021

  • December

    Established US Office in Boston

  • June

    Sirius US was officially established

2023

2022

2021

Sirius Therapeutics, Inc., all rights reserved

Privacy Policy|Contact Us

为了更好的呈现效果,移动端请竖屏浏览